{"organizations": [], "uuid": "ba3168a3b17365461ed843f1fb827d3b460fb5e3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-regains-compli/brief-mabvax-therapeutics-regains-compliance-with-nasdaqs-1-00-minimum-bid-price-maintenance-requirement-idUSFWN1QO0G2", "country": "US", "domain_rank": 408, "title": "BRIEF-MabVax Therapeutics Regains Compliance With NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.11, "site_type": "news", "published": "2018-03-06T22:18:00.000+02:00", "replies_count": 0, "uuid": "ba3168a3b17365461ed843f1fb827d3b460fb5e3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-mabvax-therapeutics-regains-compli/brief-mabvax-therapeutics-regains-compliance-with-nasdaqs-1-00-minimum-bid-price-maintenance-requirement-idUSFWN1QO0G2", "ord_in_thread": 0, "title": "BRIEF-MabVax Therapeutics Regains Compliance With NASDAQ's $1.00 Minimum Bid Price Maintenance Requirement", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "mabvax therapeutics holdings inc", "sentiment": "negative"}, {"name": "brief-mabvax therapeutics regains compliance with nasdaq", "sentiment": "negative"}, {"name": "nasdaq", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Mabvax Therapeutics Holdings Inc :\n* MABVAX THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQâ€™S $1.00 MINIMUM BID PRICE MAINTENANCE REQUIREMENT Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T22:18:00.000+02:00", "crawled": "2018-03-07T19:29:15.007+02:00", "highlightTitle": ""}